BrainScope has appointed a half-dozen members to its Advisory Board: Emily Baxi, Ph.D.; Melanie Leitner, Ph.D.; Edward Michelson, M.D.; José Hernan N. Posas III, M.D.; Jose Javier Provencio, M.D.; and Genevieve Stein-O’Brien, Ph.D. The appointments occur as the company scales its commercial footprint and expands its deep learning platform into new clinical indications, including neurodegenerative diseases and stroke.

“As we continue pioneering new frontiers in neurodiagnostics, we prioritize finding leaders who bring both deep technical and clinical knowledge along with a broad vision for the future of patient care,” BrainScope CEO Matt Adams said. “We are fortunate to have Drs. Baxi, Leitner, Michelson, Posas, Provencio and Stein-O’Brien join us, and I am certain their guidance will be a catalyst for BrainScope’s continued innovation.” 

Dr. Baxi is a director with the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at Milken Institute Strategic Philanthropy and brings a wealth of experience in science philanthropy. As a neuroscientist and educator, she advises foundations and philanthropists on the state of research to empower impactful giving, and leads large-scale research infrastructure initiatives such as the Integrated Network for Breakthrough Discoveries for bipolar disorder. Prior to her current role, she served as the executive director of the Packard Center for ALS (amyotrophic lateral sclerosis) Research at Johns Hopkins University and the program director for Answer ALS.

Dr. Leitner currently serves as chief scientific officer of the ALS Investment Fund, a social impact venture capital fund investing in disease-modifying therapies for neurodegeneration. With nearly two decades of experience in the neuroscience translational space, Dr. Leitner has consulted for more than 35 organizations across Alzheimer’s, Parkinson’s and ALS. She was part of the original ALS program team at Biogen and led the team that received the 2022 Healey International Prize for Innovation for the development of the PRO-ACT database, the largest clinical trial ALS dataset.

Dr. Michelson is professor and chair of the Department of Emergency Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center in El Paso. He earned a bachelor of science degree in biomedical engineering from MIT, an M.D. from Washington University School of Medicine in St. Louis, and completed a combined residency in internal medicine and emergency medicine at Northwestern University in Chicago. Over a 39-year academic career at five major medical schools and centers, Dr. Michelson has collaborated with BrainScope on multiple research projects for more than 15 years, including scientific publications and national meeting presentations.

Dr. Posas is a sports neurologist in the University of Virginia School of Medicine’s Department of Neurology in Charlottesville, where he is vice chair for education and associate program director for the neurology residency, and serves on the Neurology Community Committee. His work spans medical education, community engagement, and concussion clinical care and research. At UVA, Dr. Posas helped develop and launch a Resident and Fellow Leadership course with the UVA Health Leadership Institute. Nationally, he serves on the American Academy of Neurology Board of Directors and the editorial board of Continuum, and moderates and hosts the NeuroPanels educational webinar series. Dr. Posas earned his medical degree at LSU Health Sciences Center in New Orleans and completed neurology residency training at the University of Miami/Jackson Memorial Hospital, followed by a sports neurology fellowship at Kerlan Jobe Orthopaedic Clinic.

Dr. Provencio is division head of the hospital neurology division and the Louise Nerancy Professor in Neurology at the University of Virginia, where he is also the medical director of the Nerancy Neuroscience Intensive Care Unit. A prominent translational researcher focused on the inflammatory underpinnings of acute brain injuries, Dr. Provencio holds national leadership roles on the steering committee of the Curing Coma Campaign and the annual program committee of the Society of Critical Care Medicine. He has dedicated his career to improving outcomes for patients with acute neurological conditions through both clinical excellence and innovative research.

Dr. Stein-O’Brien is the Terkowitz Family Rising Professor of Brain Science and Bloomberg assistant professor of Neuroscience at JohnsHopkins University, with affiliations to the Kavli Neuroscience Discovery Institute, the McKusick-Nathans Department of Genomic Medicine, the Convergence Institute, and the Institute for Data Intensive Engineering and Science. She earned a Ph.D. in human genetics from the Johns Hopkins School of Medicine and an M.H.S. in biostatistics from the Johns Hopkins Bloomberg School of Public Health. Dr. Stein-O’Brien’s research focuses on computational and statistical methods for pattern detection and data integration in high-throughput omics data, including transfer learning approaches applied to single-cell transcriptional data to identify molecular co-regulation patterns across measurement types, tissues, and species.

Company executives said the addition of these experts further strengthens BrainScope’s ability to develop novel digital biomarkers and expands the clinical utility of electroencephalography (EEG) to aid in diagnosing and monitoring a wide range of brain-related conditions. BrainScope is reportedly the first medical device to receive U.S. Food and Drug Administration (FDA) clearance in neurology using a machine learning approach. Its recently developed deep learning platform utilizes a Large Neural Model approach to transform how brain injuries and neurological diseases are assessed and managed through noninvasive, objective diagnostic tools.

BrainScope is a commercial-stage medical neurotechnology company focused on applying artificial intelligence to brain electrical activity to develop noninvasive, objective diagnostic tools for brain health. With an FDA-cleared product already in commercial use and a robust machine and deep learning platform, BrainScope is pioneering the development of digital biomarkers to transform how brain injuries and neurological diseases are assessed and managed.